Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18815015 | 0.84 | NPC1 (0.42) | MEN1KMT2ANPC1MAPK14ITGB1 | |
| SCHEMBL4375461 | 0.77 | HTR7 (0.58) | JAK2JAK3PRCPHTR7 | |
| SCHEMBL21593091 | 0.77 | HTR7 (0.58) | JAK2JAK3PRCPHTR7 | |
| SCHEMBL4375466 | 0.77 | HTR7 (0.58) | JAK2JAK3PRCPHTR7 | |
| SCHEMBL12676418 | 0.77 | TRPM8 (0.45) | TRPM8JAK2JAK3MAPK14LMNA | |
| SCHEMBL374406 | 0.76 | — | — | |
| SCHEMBL29382825 | 0.76 | — | — | |
| SCHEMBL17591565 | 0.75 | JAK2 (0.43) | TRPM8JAK2JAK3LMNAHTT | |
| SCHEMBL30579411 | 0.75 | JAK2 (0.43) | TRPM8JAK2JAK3LMNAHTT | |
| SCHEMBL12356612 | 0.75 | TRPM8 (0.39) | NPC1TRPM8JAK2JAK3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023028338-A2 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20210309659-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2021-10-07 | — | — | US | disclosed |
| US-20200207762-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2020-07-02 | — | — | US | disclosed |
| US-10604519-B2 | 5,7-dihydro-pyrrolo-pyridine derivatives | PFIZER INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2018191587-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| US-20180002331-A1 | 5,7-Dihydro-Pyrrolo-Pyridine Derivatives | PFIZER INC. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9029359-B2 | Heteroaryl Btk inhibitors | BIOGEN IDEC MA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2485589-A1 | HETEROARYL BTK INHIBITORS | Biogen Idec MA Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011029043-A1 | HETEROARYL BTK INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | MEN1 3647/4885KMT2A 4789/4885NPC1 1118/4885 |
| US-20200071326-A1 | TAM KINASE INHIBITORS | PIK3CA, MAP3K1, MAP3K5 | MEN1 1158/4885KMT2A 680/4885NPC1 2353/4885 |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | BTK, LYN, SYK | MEN1 3861/4885KMT2A 1126/4885NPC1 3310/4885 |
| US-20210309659-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | CHRM1, CHRM5, CHRM2 | MEN1 3103/4885KMT2A 1358/4885NPC1 761/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | MEN1 4131/4885KMT2A 3629/4885NPC1 777/4885 |
| US-20200207762-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | CHRM1, CHRM5, CHRM2 | MEN1 3103/4885KMT2A 1358/4885NPC1 761/4885 |
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | CHRM1, CHRM5, CHRM2 | MEN1 3103/4885KMT2A 1358/4885NPC1 761/4885 |
| US-20180002331-A1 | 5,7-Dihydro-Pyrrolo-Pyridine Derivatives | CHRM1, CHRM5, CHRM2 | MEN1 3103/4885KMT2A 1358/4885NPC1 761/4885 |
| US-10604519-B2 | 5,7-dihydro-pyrrolo-pyridine derivatives | CHRM1, CHRM5, CHRM2 | MEN1 3103/4885KMT2A 1358/4885NPC1 761/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | MEN1 641/4885KMT2A 4507/4885NPC1 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.